ArticleJBMR plus2024

Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism.

Daniel B Hall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.